Aardvark Therapeutics, Inc. Common Stock (AARD) Financial Ratios
4 years of historical data (2022–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
0.74
↓-72% vs avg
5yr avg: 2.69
30Y Low2.7·High2.7
ROE
-221.5%
+0% vs avg
5yr avg: -221.5%
30Y Low-222%·High-222%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
AARD Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Aardvark Therapeutics, Inc. Common Stock currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Market Cap | $79M | $286M | — | — | — |
| Enterprise Value | $33M | $240M | — | — | — |
| P/E Ratio → | -1.38 | — | — | — | — |
| P/S Ratio | — | — | — | — | — |
| P/B Ratio | 0.74 | 2.69 | — | — | — |
| P/FCF | — | — | — | — | — |
| P/OCF | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
AARD EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — |
| EV / FCF | — | — | — | — | — |
AARD Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -221.5% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — |
| Operating Margin | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| ROE | -221.5% | -221.5% | — | — | — |
| ROA | -59.2% | -59.2% | -46.8% | -52.8% | -80.9% |
| ROIC | — | — | — | — | — |
| ROCE | -70.0% | -70.0% | -55.8% | -58.6% | -70.3% |
AARD Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $47M exceeds total debt of $441000, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | — | — | — |
| Debt / EBITDA | — | — | — | — | — |
| Net Debt / Equity | — | -0.44 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — |
Net cash position: cash ($47M) exceeds total debt ($441000)
AARD Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Aardvark Therapeutics, Inc. Common Stock's current ratio of 10.61x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 7.50x to 10.61x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Current Ratio | 10.61 | 10.61 | 15.05 | 7.50 | 27.72 |
| Quick Ratio | 10.61 | 10.61 | 15.05 | 7.50 | 27.72 |
| Cash Ratio | 10.43 | 10.43 | 14.95 | 7.23 | 27.07 |
| Asset Turnover | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — |
AARD Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Aardvark Therapeutics, Inc. Common Stock does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — |
| FCF Yield | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $22M | $22M | $21M | $21M |
Peer Comparison
Compare AARD with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 AARDYou | $79M | -1.4 | — | — | — | — | -221.5% | — | — |
 RYTM | $6B | -28.2 | — | — | 89.7% | -101.2% | -129.5% | -70.1% | — |
 VNDA | $361M | -1.6 | — | — | 94.0% | -70.0% | -50.9% | -32.2% | — |
 IMVT | $7B | -11.9 | — | — | — | — | -64.8% | — | — |
 CGEM | $798M | -3.5 | — | — | — | — | -44.0% | -43.5% | — |
 NUVL | $9B | -21.1 | — | — | — | — | -36.7% | -32.5% | — |
 VKTX | $3B | -9.0 | — | — | — | — | -47.3% | -44.4% | — |
 GPCR | $2B | -18.0 | — | — | — | — | -11.9% | -30.3% | — |
 TERN | $5B | -51.4 | — | — | — | — | -14.2% | -24.7% | — |
 ELVN | $2B | -22.1 | — | — | — | — | -27.0% | -32.8% | — |
 KYMR | $7B | -22.5 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
| Healthcare Median | — | 23.1 | 14.4 | 19.0 | 64.0% | -4.2% | -32.6% | -11.2% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 4 years · Updated daily
What if you invested $1,000 in AARD 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in AARD be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs AARD Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationAARD vs RYTM — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Rhythm Pharmaceuticals, Inc..
Compare NowAARD — Frequently Asked Questions
Quick answers to the most common questions about buying AARD stock.
What is Aardvark Therapeutics, Inc. Common Stock's P/E ratio?
Aardvark Therapeutics, Inc. Common Stock's current P/E ratio is -1.4x. This places it at the 50th percentile of its historical range.
What is Aardvark Therapeutics, Inc. Common Stock's ROE?
Aardvark Therapeutics, Inc. Common Stock's return on equity (ROE) is -221.5%. The historical average is -221.5%.
Is AARD stock overvalued?
Based on historical data, Aardvark Therapeutics, Inc. Common Stock is trading at a P/E of -1.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.